Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
9.12
-0.23 (-2.46%)
At close: Nov 4, 2024, 4:00 PM
9.15
+0.03 (0.33%)
Pre-market: Nov 5, 2024, 7:02 AM EST
Novavax Revenue
Novavax had revenue of $415.48M in the quarter ending June 30, 2024, a decrease of -2.11%. This brings the company's revenue in the last twelve months to $987.67M, down -38.17% year-over-year. In the year 2023, Novavax had annual revenue of $983.71M, down -50.36%.
Revenue (ttm)
$987.67M
Revenue Growth
-38.17%
P/S Ratio
1.19
Revenue / Employee
$640,095
Employees
1,543
Market Cap
1.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
| Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
| Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
| Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
| Dec 31, 2019 | 18.66M | -15.63M | -45.57% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AMN Healthcare Services | 3.23B |
| Progyny | 1.13B |
| Evotec SE | 844.79M |
| InMode | 423.75M |
| BioCryst Pharmaceuticals | 412.58M |
| STAAR Surgical Company | 341.22M |
| Ardelyx | 251.85M |
| Arcus Biosciences | 247.00M |
NVAX News
- 14 hours ago - Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024 - PRNewsWire
- 5 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Novavax, Inc. (NVAX) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 6 days ago - Novavax, Inc. (NVAX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 7 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Novavax, Inc. (NVAX) Shareholders to Inquire about Securities Investigation - Accesswire
- 8 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Novavax, Inc. (NVAX) And Encourages Investors to Connect - Accesswire
- 12 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Novavax, Inc. (NVAX) Stockholders to Inquire about Securities Investigation - Accesswire
- 13 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Novavax, Inc. (NVAX) and Encourages Investors to Learn More About the Investigation - Accesswire
- 14 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Novavax, Inc. (NVAX) And Encourages Investors to Reach Out - Accesswire